Outlook Therapeutics CEO to discuss company developments at Piper Sandler Healthcare Conference, December 2, 2025.
Quiver AI Summary
Outlook Therapeutics, Inc. announced that CEO Bob Jahr will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:00 AM ET. The company, which focuses on improving the standard of care for retinal diseases using bevacizumab, invites qualified investors to meet with management in person at the conference. A live and archived webcast of the chat will be available on their website. Outlook Therapeutics is advancing its product, LYTENAVA™ (bevacizumab-vikg), the first ophthalmic formulation of bevacizumab, which has received marketing authorization in Europe for wet AMD and is currently investigational in the U.S.
Potential Positives
- Participation of CEO Bob Jahr in a prominent healthcare conference enhances company visibility and credibility in the biopharmaceutical sector.
- Management's availability for one-on-one meetings with investors indicates a commitment to engaging with stakeholders and fostering investor relations.
- The commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK represents a significant step in the company's growth and market penetration.
- Receiving Marketing Authorization from the European Commission and MHRA positions Outlook Therapeutics as a leader in the development of innovative treatments for retinal diseases.
Potential Negatives
- ONS-5010/LYTENAVA™ is still classified as investigational in the United States, indicating that the company has not yet achieved regulatory approval for a key market.
- The press release does not mention any specific timelines for U.S. approval, which may raise concerns about potential delays and the overall progress of the product.
- The focus on European market launch without U.S. approval could suggest limited revenue potential in the immediate future, potentially affecting investor confidence.
FAQ
What is the date and time of the fireside chat?
The fireside chat will take place on December 2, 2025, at 10:00 AM ET.
Who will represent Outlook Therapeutics at the conference?
Bob Jahr, the Chief Executive Officer of Outlook Therapeutics, will participate in the fireside chat.
How can I access the live webcast of the fireside chat?
The live webcast can be accessed on the Events page in the Investors section of the company's website.
What is LYTENAVA™ and its significance?
LYTENAVA™ is the first ophthalmic formulation of bevacizumab approved for treating wet AMD, enhancing existing care standards.
Is ONS-5010/LYTENAVA™ approved in the United States?
It is currently investigational in the U.S. and requires approval to be used for retinal indications.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OTLK Hedge Fund Activity
We have seen 19 institutional investors add shares of $OTLK stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SPHERA FUNDS MANAGEMENT LTD. removed 857,142 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,371,427
- SCHONFELD STRATEGIC ADVISORS LLC removed 649,639 shares (-47.6%) from their portfolio in Q3 2025, for an estimated $688,617
- MORGAN STANLEY removed 424,824 shares (-99.8%) from their portfolio in Q3 2025, for an estimated $450,313
- TANG CAPITAL MANAGEMENT LLC removed 400,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $640,000
- STEWARD PARTNERS INVESTMENT ADVISORY, LLC removed 366,187 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $388,158
- FMR LLC removed 170,396 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $180,619
- SQUAREPOINT OPS LLC removed 155,624 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $164,961
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OTLK Analyst Ratings
Wall Street analysts have issued reports on $OTLK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 09/22/2025
To track analyst ratings and price targets for $OTLK, check out Quiver Quantitative's $OTLK forecast page.
$OTLK Price Targets
Multiple analysts have issued price targets for $OTLK recently. We have seen 3 analysts offer price targets for $OTLK in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- Douglas Tsao from HC Wainwright & Co. set a target price of $1.0 on 09/30/2025
- Edward Woo from Ascendiant Capital set a target price of $8.0 on 09/22/2025
- Daniil Gataulin from Chardan Capital set a target price of $3.0 on 08/28/2025
Full Release
ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the Piper Sandler 37 th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET.
In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the Company’s website ( outlooktherapeutics.com ). The webcast replay will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
[email protected]
